DPI-287

• CAT Number: I026500
• CAS Number: 519058-13-0
• Molecular Formula: C31H39N3O2
• Molecular Weight: 485.67
• Purity: 98%
• Synonyms: DPI-287; DPI 287; DPI287
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: 4-[(R)-[(2S,5R)-4-benzyl-2,5-dimethylpiperazin-1-yl]-(3-hydroxyphenyl)methyl]-N,N-diethylbenzamide
• InChI: InChI=1S/C31H39N3O2/c1-5-32(6-2)31(36)27-17-15-26(16-18-27)30(28-13-10-14-29(35)19-28)34-21-23(3)33(20-24(34)4)22-25-11-8-7-9-12-25/h7-19,23-24,30,35H,5-6,20-22H2,1-4H3/t23-,24+,30-/m1/s1
• InChIKey: PQMGDEIHRXQPCQ-FSGGQHMVSA-N
• SMILES: CCN(CC)C(=O)C1=CC=C(C=C1)[C@H](C2=CC(=CC=C2)O)N3C[C@H](N(C[C@@H]3C)CC4=CC=CC=C4)C

DPI-287（Cat No.:I026500）is an investigational small molecule drug being developed by DPI (formerly known as Design Pharmaceuticals). It is primarily being studied for its potential in treating conditions involving neurodegeneration, particularly Alzheimer’s disease. The drug targets a specific protein involved in disease progression, aiming to slow or halt cognitive decline. While still in the early stages of clinical trials, DPI-287 shows promise due to its unique mechanism of action and potential to address unmet needs in neurodegenerative therapy. Further research is needed to establish its safety and efficacy.